Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer

Current Medical Research and Opinion, 2016 11; 32(11): 1911-1918. e-pub ahead of print 2016/08/05; doi: 10.1080/03007995.2016.1220934

Time to progression (TTP) is a surrogate marker of overall survival (OS). However, OS is also dependent on post-progression survival (PPS). This study evaluated the association between TTP and the duration of PPS among adult patients who received ceritinib (Zykadia 1 ) for the treatment of advanced anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC).

View abstract

Authors

Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.